Navigation Links
Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories' New Drug Application (NDA) for Efavirenz Tablets
Date:12/22/2009

PITTSBURGH, Dec. 22 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.

Mylan President Heather Bresch commented: "This New Drug Application represents another successful innovation by Matrix in the fight against HIV/AIDS. Our HIV/AIDS antiretroviral (ARV) franchise continues to grow and to bring more affordable, high quality medications to patients in the developing world. We are extremely pleased to be able to add these new dosages to the basket of treatment options currently available to the medical community, and to expand our portfolio of products for treating pediatric HIV/AIDS."

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (nNRTI) that has been found to be effective in many combination regimens for the treatment of HIV infection, both in treatment-naive and in treatment-experienced individuals.

The FDA's tentative approval under PEPFAR means that Matrix's product meets all of the agency's manufacturing quality, safety and efficacy standards. Although existing patents or exclusivity prevent its marketing in the U.S., the product will be eligible for purchase outside the U.S. in many developing countries.

Matrix's wide range of ARV products includes active pharmaceutical ingredients and first- and second-line finished doses. The company's emphasis on producing affordable products has allowed it to drive down the average annual cost per person of effective therapies. Approximately 30% of people living with HIV/AIDS in developing countries who are receiving treatment depend on Matrix ARV products.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.

SOURCE Mylan Inc.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Added to NASDAQ-100 Index
2. Mylan Receives Approval for Generic Version of Antiepileptic Keppra(R) 1000 mg
3. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
4. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
5. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
6. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
8. The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
9. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
10. CareCentrix Receives URAC Health Utilization Management Accreditation
11. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
(Date:6/7/2017)... 2017  Novavax, Inc., (Nasdaq: NVAX ) today ... trials of its RSV F protein recombinant nanoparticle vaccine candidate ... been published in the journal Vaccine ... prior scientific conferences). The Company previously announced top line ... developing the RSV F Vaccine with the goal of protecting ...
(Date:6/3/2017)... INDIANAPOLIS , June 3, 2017  Eli ... today announced that results from the Phase 3 ... kinase (CDK)4 & 6 inhibitor, in combination with ... treatment with fulvestrant alone in women with hormone-receptor-positive ... advanced breast cancer who have relapsed or progressed ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... ... services, is proud to announce the guest speaker lineup* for its second annual ... Alliance of Healthcare Purchaser Coalitions; Dr. Keith Fernandez of Privia Health; and Lisa ...
(Date:6/28/2017)... PA (PRWEB) , ... June 28, 2017 , ... ... host a one-day corporate governance program for mid-market executives as a kick-off to ... be held Sunday, Sept. 24, 2017 on the University of Pennsylvania campus, followed ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... management and financial planning assistance to clients in southern Montana, is announcing a ... by Zoo Montana. , The outreach programs offered by Zoo Montana provide students ...
(Date:6/27/2017)... ... June 27, 2017 , ... Excel Medical, the leader ... the position of Executive Vice President, Sales and Marketing. Finnegan is a widely ... medical device sales leadership. He has received industry recognition for innovations and new ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):